EMERYVILLE, Calif. and PARIS, Dec. 5, 2013 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) and Total (Paris:TOTF) announced today the formation of Total Amyris BioSolutions B.V., a 50-50 joint venture that now holds exclusive rights and a license under Amyris's intellectual property to produce and market renewable diesel and jet fuel from Amyris's renewable farnesene. TOTAL is Amyris's largest investor, holding approximately 18% of its outstanding common stock, and is deeply committed to the development of next-generation renewable fuels from biomass.
About the TechnologyAmyris has developed advanced microbial engineering and screening technologies that modify the way microorganisms process sugars. Amyris is using this industrial synthetic biology platform to design microbes, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable chemical and transportation fuel products. This technology may help make it possible for producers to blend renewable hydrocarbons produced from sustainable biomass and organic waste into conventional fuel, in significant proportions. Renewable fuels developed by TOTAL and Amyris may deliver energy density and engine performance comparable to the best petroleum fuels. Amyris operates laboratories and a pilot plant in California as well as an industrial-scale facility located in the state of São Paulo, Brazil. Amyris has been and will continue supplying renewable fuels in Brazil, including diesel to over 300 public transit buses in large metropolitan areas. Amyris also plans to initiate sales of renewable jet fuel in Brazil once it achieves ASTM validation. To learn more about Amyris and TOTAL's collaborations, visit http://amyr.is/biosolutions About the Companies Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of molecules -- flexible building blocks that can be used in a wide range of products. Amyris's initial portfolio of commercial products is based on Biofene®, Amyris's brand of renewable farnesene, a long-chain hydrocarbon. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil. www.amyris.com TOTAL is one of the largest integrated oil and gas companies in the world, with activities in more than 130 countries. The Group is also a first rank player in chemicals. Its 97,000 employees put their expertise to work in every part of the industry – exploration and production of oil and natural gas, refining and marketing, new energies, trading, and chemicals. TOTAL is working to help satisfy the global demand for energy, both today and tomorrow. The Group holds a 66% stake in SunPower, a world leader in solar energy, and an approximately 18% stake in Amyris, an integrated renewable products company. Additionally, TOTAL is actively engaged in a number of renewable R&D projects, such as solar and biomass. www.total.com Amyris Forward-Looking Statements This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as commercialization of Biofene-based fuels through a joint venture, demand for and benefits of such fuels, successful completion of R&D program, receipt of ASTM validation, and expansion of fuel sales) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on November 5, 2013. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.
CONTACT: Amyris, Inc. Joel Velasco (510) 740-7481 email@example.com TOTAL Quentin Vivant, Press officer +33 1 41 35 37 44 firstname.lastname@example.org